Takeda ups its offer for Shire
Takeda has put forward a new proposed bid for Shire, increasing the cash portion of the deal. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_ups_its_offer_for_shire_1232830Takeda has put forward a new proposed bid for Shire, increasing the cash portion of the deal. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_ups_its_offer_for_shire_1232830The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/eu_oks_mundipharmas_neulasta_biosimilar_1265039NHS Confederation chief executive Niall Dickson is warning that the NHS is “under intolerable strain”, after the latest performance data continue to show growing demand and missed targets. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nhs_under_intolerable_strain_1244161GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of
by Selina McKee
www.pharmatimes.com/news/gw_completes_epidiolex_submission_1209905Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_gets_us_nod_for_shire_buy_1243748The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/eu_green_light_for_new_humira_biosimilar_1252910Sanofi Pasteur and MSD have announced the end of their European vaccines joint venture so that their own “distinct growth strategies” can be pursued instead. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sanofi,_msd_to_dismantle_vaccines_jv_1020306Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/boehringer_buys_viratherapeutics_1252039AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_completes_acquisition_of_zs_pharma_972294Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_turns_down_takedas_advances_1232652